STATEMENT BY THE HEALTH DIVISION REGARDING HORMONE REPLACEMENT THERAPY (HRT)
Following an extensive European-wide review of the balance of risks and benefits of HRT in response to growing concerns about the safety of HRT in long-term use, the review found that:-
1. For the treatment of menopausal symptoms, HRT is beneficial in the short-term with the minimum effective dose used for the shortest duration.
2. The balance of risks and benefits of HRT when used in the long-term for preventing osteoporosis, suggest that it should not be the first choice of therapy.
3. HRT is of no benefit in healthy women without symptoms.
| In | conjunction with other European medicinal regulatory authorities, the Medicines Regulatory Unit (MRU) is advising prescribers that conventional oestrogen-only and oestrogen plus progestogen(combined) HRT should no longer be considered as first choice of therapy for prevention of osteoporosis. The MRU advises women currently using these products that there is no need for immediate action but that they should make a routine appointment with their doctor to discuss the most appropriate options available to them based on their personal medical history. |
| Findings | published in 2003 from the notable Women’s Health Initiative (WHI) study and the UK Million Women Study, as well as previous scientific research, indicate that HRT is associated with a duration-dependent increase in the risk of breast cancer, endometrial cancer and ovarian cancer. In addition HRT is no longer thought to have a benefical effect on cardiovascular disease and has been shown to increase the risk of heart attacks and venous thromboembolism (VTE or blood clots) especially in the first year, and to increase the risk of stroke. The risk of most of these conditions increases with age therefore the overall risks increase the longer HRT is taken. |
| Recommendations | for medical practitioners are: |
· For the treatment of menopausal (climateric) symptoms that adversely affect quality of life the balance of risks and benefits of HRT is generally favourable. However the lowest effective dose should be used for the shortest possible duration; each decision to start HRT should be made on an individual basis with a fully informed woman; and treatment should be re-evaluated at least annually in light of new knowledge and any changes in a woman’s risk factors.
· For the prevention of osteoporosis in woman with an increased risk of fractures the benefit-risk balance of HRT, with different kinds of oestrogens and oestrogen-progestogen combinations is, on the basis of available evidence, not favourable. Therefore it is not favourable as first line treatment for this indication.
· The use of HRT for the prevention of osteoporosis in postmenopausal women at high risk for future fractures who are intolerant to other drugs approved for the prevention of osteoporosis, after careful assessment of the individual benefit-risk balance, remains a treatment option.
For further information contact:
Medicines Regulatory Unit,
198, Rue d’Argens,
Gzira
Tel No 356 23439000
Fax No 356 23439161
http://www.health.gov.mt/mru
| Note | to Editors |
| Throughout | Europe, Hormone Replacement Therapy (HRT) products are indicated for the treatment of menopausal symptoms, and many are also licensed for the prevention of osteoporosis. |
A statement regarding this review is available via the website of the European Medicines Evaluation Agency (EMEA) www.emea.eu.int
Information is also available on the website of the Heads of European Medicines Regulatory Agency http://heads.medagencies.org
Stqarrijiet Oħra:
PR261936
STQARRIJA MILL-UFFIĊĊJU TAD-DEPUTAT PRIM MINISTRU U MINISTERU GĦAS-SAĦĦA I...
PR261935en